| Sequence 1: | NP_002323.2 | Gene: | LRP1 / 4035 | HGNCID: | 6692 | Length: | 4544 | Species: | Homo sapiens |
|---|---|---|---|---|---|---|---|---|---|
| Sequence 2: | NP_572563.3 | Gene: | mgl / 8674055 | FlyBaseID: | FBgn0261260 | Length: | 4769 | Species: | Drosophila melanogaster |
| Alignment Length: | 4459 | Identity: | 1631/4459 - (36%) |
|---|---|---|---|
| Similarity: | 2323/4459 - (52%) | Gaps: | 472/4459 - (10%) |
- Green bases have known domain annotations that are detailed below.
|
Human 27 CSPKQFACRDQITCISKGWRCDGERDCPDGSDEAPEICPQSKAQRCQPNEHNC-----LGTELCV 86
Human 87 PMSRLCNGVQDCMDGSDEGPHCRELQGNCSRLGCQHHCVPTLDGPTCYCNSSFQLQADGKTCKDF 151
Human 152 DECSVYGTCSQLCTNTDGSFICGCVEGYLLQPDNRSCKAKNEPVDRPPVLLIANSQNILATYLSG 216
Human 217 AQVSTITPTSTRQTTA---MDFSYANETVCWVHVGDSAAQT-----QLKCA-----RMPGLKGFV 268
Human 269 DEHTINISLSLHHVEQMAIDWLTGNFYFVDDIDDRIFVCNRNGDTCVTLLDLELYNPKGIALDPA 333
Human 334 MGKVFFTDYGQIPKVERCDMDGQNRTKLVDSKIVFPHGITLDLVSRLVYWADAYLDYIEVVDYEG 398
Human 399 KGRQTIIQGILIEHLYGLTVFENYLYATNSDNANAQQKTSVIRVNRFNS-TEYQVV-----TRVD 457
Human 458 KGGALHIYHQRRQPRVRSHACENDQYGKPGGCSDICLLANSHKART-----CRCRSGFSLGSDGK 517
Human 518 SCKKPEHELFLVYGKGRPGIIRGMDMGAKVP--DEHMIPIENLMNPRA----LDFHAETGFIYFA 576
Human 577 DTTSYLIGRQKIDGTERETILKDGIHNVEGVAVDWMGDNLYWTDDGPKKTISVARLEKAAQTRKT 641
Human 642 LIEGKMTHPRAIVVDPLNGWMYWTDWEEDPKDSRRGRLERAWMDGSHRDIFVTSKTVLWPNGLSL 706
Human 707 DIPAGRLYWVDAFYDRIETILLNGTDRKIVYEGPELNHAFGLCHHGNYLFWTEYRSGSVYRLERG 771
Human 772 VGGAPPTVTLLRSERPPIFEIRMYDAQQQQVG-TNKCRVNNGGCSSLCLATP------------- 822
Human 823 ----GSRQ--CACAEDQVLDADGVTCLANPSYVPPPQCQPG--EFACANSRCIQERWKCDGDNDC 879
Human 880 LDNSDEAPALCHQHTCPSDRFKCENNRCIPNRWLCDGDNDCGNSEDESNATCSARTCPPNQFSCA 944
Human 945 SGRCIPISWTCDLDDDCGDRSDESASCAYPTCFPLTQFTC-NNGRCININWRCDNDNDCGDNSDE 1008
Human 1009 AGCSH-SCSSTQFKCNSGR-CIPEHWTCDGDNDCGDYSDETHANCTNQATRPPGGCHTDE-FQCR 1070
Human 1071 LDGLCIPLRWRCDGDTDCMDSSDEKSCEGVTHVCDPSVKFGCKDSARCISKAWVCDGDNDCEDNS 1135
Human 1136 DEENCESLACRPP--------------SHPCANNTSVCLPPDKLCDGNDDCGDGSDEGELCD--Q 1184
Human 1185 CSLNNGGCSHNCSVAPGEGIVCSCPLGMELGPDNHTCQIQSYCAKHLKCSQKCDQNKFSVKCSCY 1249
Human 1250 EGWVLEPDGESCRSLDPFKPFIIFSNRHEIRRIDLHKGDYSVLVPGLRNTIALDFHLSQSALYWT 1314
Human 1315 DVVEDKIYRGKLLDNGALTSFEVVIQYGLATPEGLAVDWIAGNIYWVESNLDQIEVAKLDGTLRT 1379
Human 1380 TLLAGDIEHPRAIALDPRDGI--LFWTDWDASLPRIEAASMSGAGRRTVHRETGSGGWPNGLTVD 1442
Human 1443 YLEKRILWIDARSDAIYSARYDGSGHMEVLRGHEFLSHPFAVTLYGGEVYWTDWRTNTLAKANKW 1507
Human 1508 TGHNVTVVQRTNTQPFDLQVYHPSRQPMAPNPCEANGGQGPCSHLCLINYN--RTVSCACPHLMK 1570
Human 1571 LHKDNTTCYEFKKFLLYARQMEIRGVDLD-----------APYYNYIISFTVPDIDNVTVLDYDA 1624
Human 1625 REQRVYWSDVRTQAIKRAFINGT-----------GVET-VVSADLPNAHGLAVDWVSRNLFWTSY 1677
Human 1678 DTNK--KQINVARLDGSFKNAVV--------QGLEQPHGLVVHPLRGKLYWTDGD------NISM 1726
Human 1727 ANMDGSNRTLLFSGQKGPVGLAIDFPESKLYWISSGNHTINRCNLDGSGLEVIDAMRSQ-LGKAT 1790
Human 1791 ALAIMGDKLWWADQVSEKMGTCSKADGSGSVVLRNSTTLVMHMKVYDESIQLDHKGTNPCSVNNG 1855
Human 1856 DCSQLCLPTSETTRSCMCTAGYSLRSGQQACEGVGSFLLYSVHEGIRGIPLDPNDKSDALVPVSG 1920
Human 1921 TSLAV-GIDFHAENDTIYWVDMG---LSTISRAKRDQTWREDVVTNGIGR--VEGIAVDWIAGNI 1979
Human 1980 YWTD--QGFDVIEVARLNGSFRYVVISQGLDKPRAITVHPEKGYLFWTEWGQYPRIERSRLDGTE 2042
Human 2043 RVVLVNVSISWPNGISVDYQDGKLYWCDARTDKIERIDLETGENREVVLSSNNMDM---FSVSVF 2104
Human 2105 EDFIYWSDRTHANGSIKRGSKDNATD-SVPLRTGIGVQLKDIKVF--NRDRQKGTNVCA-VANGG 2165
Human 2166 CQQLCL-----------YRGRGQRACACAHGMLAEDGASCREYAGYLLYSERTILKSIHLSDERN 2219
Human 2220 LNAPVQPFEDPEHMKNVIALAFDYRAGTSPGTPNRIFFSDIH-FGNI--QQINDDGSRRITIVEN 2281
Human 2282 VG-SVEGLAYHRGWDTLYWTSYTTSTITRHTVDQTRPGAFERETVITMSGDDHPRAFVLDECQNL 2345
Human 2346 MFWTNWNEQHPS--IMRAALSGANVLTLIEKDIRTPNGLAIDHRAEKLYFSDATLDKIERCEYDG 2408
Human 2409 SHRYVILKSEPVHPFGLAVYGEHIFWTDWVRRAVQRANKHVGSNMKLLRVDIPQQPMGIIAVAND 2473
Human 2474 TNSCELSPCRINNGGCQDLCLLTHQGHVNCSCRGG-RILQDDLTCRAVNSSCRAQDEFECANGEC 2537
Human 2538 INFSLTCDGVPHCKDKSDEKPSYCNSRRCKKTFRQCSNGRCVSNMLWCNGADDCGDGSDEIPCNK 2602
Human 2603 TACGVGEFRCRDGTCIGNSSRCNQFVDCED--ASDE------MNCSATDC-SSYFRLGVKGVLFQ 2658
Human 2659 PCERTSLCYAPSWVCDGANDCGDYSDERDCPGVKRPRCPLNYFACPSGRCIPMSWTCDKEDDCEH 2723
Human 2724 GEDE--THC---NKFCSEAQFECQNHRCISKQWLCDGSDDCGDGSDE--AAHCEGKTCG-PSSFS 2780
Human 2781 CPGTH-----VCVPERWLCDGDKDCADGADESIAA-GCLYNSTCDDREFMCQNRQCIPKHFVCDH 2839
Human 2840 DRDCADGSDESPEC--EYPTCGPSEFRCANGRCLSSRQWECDGENDCHDQSDEAPKNPHCTSQEH 2902
Human 2903 KCNASSQFLCSSGRCVAEALLCNGQDDCGDSSDERG-CHINECLSRKLSGCSQDCEDLKIGFKCR 2966
Human 2967 CRPGFRLKDDGRTCADVDEC-STTFPCSQRCINTHGSYKCLCVEGYAPRGGDPHSCKAVTDEEPF 3030
Human 3031 LIFANRYYLRKLNLDGSNYTLLKQGLNNAVALDFDYREQMIYWTDVTTQGSMIRRMHLNGSNVQV 3095
Human 3096 LHRTGLSNPD-----GLAVDWVGGNLYWCDKGRDTIEVSKLNGAYRTVLVSSGLREPRALVVDVQ 3155
Human 3156 NGYLYWTDWGDHSLIGRIGMDGSSRSVIVDTK--ITWPNGLTLDYVTERIYWADAREDYIEFASL 3218
Human 3219 DGSNRHVVLS-QDIPHIFALTLFEDYVYWTDWETKSINRAHKTTGTNKTLLISTLHRPMDLHVFH 3282
Human 3283 ALRQPDVPNHPCKVNNGGCSNLCLLSPG--------GGH--------KCACPTNFYLGSDGRTCV 3331
Human 3332 SNCTASQFVC--KNDKCIPFWWKCDTEDDCGDHSDEPPDCPEFKCRPGQFQCSTGICTNPAFICD 3394
Human 3395 GDNDCQDNSDEANCDIHVCLPSQFKCTNTNRCIPGIFRCNGQDNCGDGEDERD--CPEVTCAP-N 3456
Human 3457 QFQCSITKRCIPRVWVCDRDNDCVDGSDEPA-NCTQMTCGVDEFRC--KDSGRCIPARWKCDGED 3518
Human 3519 DCGDGSDEPKEECDERTCEP-YQFRCKNNRCVPGRWQCDYDNDCGDNSDEESCT----PRPCSES 3578
Human 3579 EFSCANGRCIAGRWKCDGDHDCADGSDEKDCTP-RCDMDQFQCKSGHCIPLRWRCDADADCMDGS 3642
Human 3643 DEEACG---TGVRTCPLDEFQCNNTLCKPLAWKCDGEDDCGDNSDENPEECARFVCPPNRPFRCK 3704
Human 3705 NDRVCLWIGRQCDGTDNCGDGTDEEDCEPPTAHTTHCKDKKEFLCRNQRCLSSSLRCNMFDDCGD 3769
Human 3770 GSDEEDCSIDPKLTSCATNASICGDEARCVRTEKAAY-CACRSGF-HTVPGQPGCQDINECL-RF 3831
Human 3832 GTCSQLCNNTKGGHLCSCARNFMKT---HNTCKAEGSEYQVLYIADDNEIRSLFPGHPHSAYEQA 3893
Human 3894 FQGDESVRIDAMDVHVKAGRVYWTNWHTGTISYRSLPPAAPPTTSNRHRRQIDRGVTH-LNISGL 3957
Human 3958 KMPRGIAIDWVAGNVYWTD------SGRDVIEVAQMKGENRKTLISGMIDEPHAIVVDPLRGTMY 4016
Human 4017 WSDWGNHPKIETAAMDGTLRETLVQDNIQWPTGLAVDYHNER-LYWADAKLSVIGSIRLNGT--D 4078
Human 4079 PIVAADSKRGLSHPFSIDVFEDYIYGVTYINNRVFKIHKFGHSPLVNLTGGLSHASDVVLYHQHK 4143
Human 4144 -QPEVTNPCDRKKCEWLCLLSPSGPVCTCPNGKRLDNGTCVPVPSPTPPP--------------D 4193
Human 4194 APRPGTCNLQCFNGGSCFLNARRQPKCRCQPRYTGDKCE 4232 |
| Gene | Sequence | Domain | Region | External ID | Identity |
|---|---|---|---|---|---|
| LRP1 | NP_002323.2 | LDLa | 26..59 | CDD:197566 | 13/31 (42%) |
| Ldl_recept_a | 71..104 | CDD:395011 | 16/37 (43%) | ||
| FXa_inhibition | 119..148 | CDD:464251 | 10/28 (36%) | ||
| FXa_inhibition | 158..188 | CDD:464251 | 16/29 (55%) | ||
| LY | 275..314 | CDD:214531 | 8/38 (21%) | ||
| LDL-receptor class B 1 | 292..334 | 12/41 (29%) | |||
| LY | 316..358 | CDD:214531 | 17/41 (41%) | ||
| LDL-receptor class B 2 | 335..378 | 14/42 (33%) | |||
| LY | 361..401 | CDD:214531 | 18/39 (46%) | ||
| LDL-receptor class B 3 | 379..422 | 18/42 (43%) | |||
| FXa_inhibition | 486..519 | CDD:464251 | 12/37 (32%) | ||
| LY | 551..593 | CDD:214531 | 15/45 (33%) | ||
| LDL-receptor class B 4 | 571..613 | 18/41 (44%) | |||
| LY | 594..633 | CDD:214531 | 16/38 (42%) | ||
| LDL-receptor class B 5 | 614..659 | 17/44 (39%) | |||
| LY | 640..689 | CDD:214531 | 17/48 (35%) | ||
| LDL-receptor class B 6 | 660..710 | 17/49 (35%) | |||
| LY | <700..733 | CDD:214531 | 16/32 (50%) | ||
| LDL-receptor class B 7 | 711..754 | 15/42 (36%) | |||
| FXa_inhibition | 807..842 | CDD:464251 | 16/53 (30%) | ||
| LDLa | 853..885 | CDD:197566 | 19/33 (58%) | ||
| LDLa | 895..928 | CDD:238060 | 16/32 (50%) | ||
| LDLa | 935..967 | CDD:197566 | 19/31 (61%) | ||
| LDLa | 978..1011 | CDD:238060 | 16/33 (48%) | ||
| LDLa | 1015..1048 | CDD:238060 | 17/33 (52%) | ||
| LDLa | 1062..1097 | CDD:238060 | 17/35 (49%) | ||
| LDLa | 1104..1140 | CDD:238060 | 16/35 (46%) | ||
| LDLa | 1145..1178 | CDD:238060 | 15/46 (33%) | ||
| FXa_inhibition | 1185..1221 | CDD:464251 | 14/35 (40%) | ||
| LDL-receptor class B 8 | 1309..1355 | 17/45 (38%) | |||
| Vgb | 1310..>1503 | CDD:443399 | 74/194 (38%) | ||
| LY | 1336..1376 | CDD:214531 | 19/39 (49%) | ||
| LDL-receptor class B 9 | 1356..1398 | 16/41 (39%) | |||
| LY | 1380..1423 | CDD:214531 | 17/44 (39%) | ||
| LDL-receptor class B 10 | 1399..1445 | 20/47 (43%) | |||
| LDL-receptor class B 11 | 1446..1490 | 14/43 (33%) | |||
| LDL-receptor class B 12 | 1491..1531 | 17/39 (44%) | |||
| LY | 1613..1649 | CDD:214531 | 10/46 (22%) | ||
| LDL-receptor class B 13 | 1627..1669 | 12/53 (23%) | |||
| LY | 1650..1693 | CDD:214531 | 15/45 (33%) | ||
| LDL-receptor class B 14 | 1670..1713 | 12/52 (23%) | |||
| LY | 1697..1734 | CDD:214531 | 10/50 (20%) | ||
| LDL-receptor class B 15 | 1714..1753 | 14/44 (32%) | |||
| LY | 1734..1775 | CDD:214531 | 9/40 (23%) | ||
| LDL-receptor class B 16 | 1754..1798 | 9/44 (20%) | |||
| FXa_inhibition | 1850..1886 | CDD:464251 | 14/35 (40%) | ||
| YncE | 1872..2084 | CDD:442618 | 73/219 (33%) | ||
| LDL-receptor class B 17 | 1934..1976 | 14/46 (30%) | |||
| LY | 1959..1999 | CDD:214531 | 18/43 (42%) | ||
| LDL-receptor class B 18 | 1977..2019 | 16/43 (37%) | |||
| LDL-receptor class B 19 | 2020..2063 | 16/42 (38%) | |||
| Ldl_recept_b | 2020..2061 | CDD:459654 | 15/40 (38%) | ||
| LY | 2045..2087 | CDD:214531 | 14/41 (34%) | ||
| LDL-receptor class B 20 | 2064..2107 | 11/45 (24%) | |||
| FXa_inhibition | 2159..2194 | CDD:464251 | 18/46 (39%) | ||
| LDL-receptor class B 21 | 2253..2294 | 15/44 (34%) | |||
| LDL-receptor class B 22 | 2295..2343 | 11/47 (23%) | |||
| LDL-receptor class B 23 | 2344..2388 | 15/45 (33%) | |||
| Ldl_recept_b | 2344..2386 | CDD:459654 | 14/43 (33%) | ||
| LY | 2370..2411 | CDD:214531 | 18/40 (45%) | ||
| LDL-receptor class B 24 | 2389..2431 | 15/41 (37%) | |||
| LDL-receptor class B 25 | 2432..2473 | 15/40 (38%) | |||
| FXa_inhibition | 2482..2517 | CDD:464251 | 12/35 (34%) | ||
| LDLa | 2527..2557 | CDD:238060 | 13/29 (45%) | ||
| LDLa | 2566..2600 | CDD:238060 | 14/33 (42%) | ||
| LDLa | 2605..2639 | CDD:238060 | 17/41 (41%) | ||
| LDLa | <2666..2688 | CDD:238060 | 14/21 (67%) | ||
| LDLa | 2696..2730 | CDD:238060 | 19/35 (54%) | ||
| LDLa | 2734..2765 | CDD:197566 | 13/30 (43%) | ||
| LDLa | 2773..2806 | CDD:197566 | 15/38 (39%) | ||
| LDLa | 2817..2849 | CDD:197566 | 15/31 (48%) | ||
| LDLa | 2857..2890 | CDD:197566 | 16/32 (50%) | ||
| LDLa | 2907..2939 | CDD:238060 | 14/32 (44%) | ||
| cEGF | 2964..2985 | CDD:463661 | 10/20 (50%) | ||
| EGF_CA | 2982..>3011 | CDD:214542 | 15/29 (52%) | ||
| LY | 3049..3093 | CDD:214531 | 18/43 (42%) | ||
| LDL-receptor class B 26 | 3069..3113 | 11/48 (23%) | |||
| LY | 3094..3136 | CDD:214531 | 16/46 (35%) | ||
| LDL-receptor class B 27 | 3114..3156 | 17/41 (41%) | |||
| LY | 3138..3180 | CDD:214531 | 20/41 (49%) | ||
| LDL-receptor class B 28 | 3157..3200 | 21/44 (48%) | |||
| LY | 3182..3223 | CDD:214531 | 22/42 (52%) | ||
| LDL-receptor class B 29 | 3201..3243 | 25/42 (60%) | |||
| LY | 3224..3264 | CDD:214531 | 23/40 (58%) | ||
| LDL-receptor class B 30 | 3244..3284 | 21/39 (54%) | |||
| FXa_inhibition | 3294..3330 | CDD:464251 | 21/51 (41%) | ||
| LDLa | 3334..3365 | CDD:238060 | 18/32 (56%) | ||
| LDLa | 3374..3408 | CDD:238060 | 19/33 (58%) | ||
| LDLa | 3413..3448 | CDD:238060 | 16/36 (44%) | ||
| LDLa | 3452..3485 | CDD:197566 | 18/33 (55%) | ||
| LDLa | 3493..3526 | CDD:197566 | 15/34 (44%) | ||
| LDLa | 3536..3570 | CDD:238060 | 19/34 (56%) | ||
| LDLa | 3575..3609 | CDD:238060 | 21/33 (64%) | ||
| LDLa | 3613..3647 | CDD:238060 | 19/33 (58%) | ||
| LDLa | 3653..3685 | CDD:197566 | 19/31 (61%) | ||
| LDLa | 3695..3731 | CDD:238060 | 18/35 (51%) | ||
| LDLa | 3746..3776 | CDD:238060 | 13/29 (45%) | ||
| YncE | 3862..4064 | CDD:442618 | 67/209 (32%) | ||
| LDL-receptor class B 31 | 3912..3954 | 9/42 (21%) | |||
| Recognition site for proteolytical processing. /evidence=ECO:0000255 | 3940..3943 | 0/2 (0%) | |||
| LY | 3955..3992 | CDD:214531 | 14/42 (33%) | ||
| LDL-receptor class B 32 | 3970..4012 | 13/47 (28%) | |||
| LDL-receptor class B 33 | 4013..4056 | 21/42 (50%) | |||
| Ldl_recept_b | 4013..4054 | CDD:459654 | 19/40 (48%) | ||
| LY | 4037..4078 | CDD:214531 | 16/43 (37%) | ||
| LDL-receptor class B 34 | 4057..4101 | 19/46 (41%) | |||
| Interaction with MAFB. /evidence=ECO:0000250|UniProtKB:Q91ZX7 | 4445..4544 | ||||
| NPXY motif | 4502..4507 | ||||
| mgl | NP_572563.3 | LDLa | 157..189 | CDD:238060 | |
| LDLa | 204..236 | CDD:238060 | |||
| LDLa | 292..327 | CDD:238060 | |||
| LDLa | 332..366 | CDD:238060 | 16/39 (41%) | ||
| LDLa | 371..412 | CDD:238060 | 18/40 (45%) | ||
| vWFA | <447..488 | CDD:469594 | 22/40 (55%) | ||
| YncE | <492..634 | CDD:442618 | 37/161 (23%) | ||
| NHL | 573..>716 | CDD:302697 | 52/160 (33%) | ||
| NHL repeat | 573..610 | CDD:271320 | 9/51 (18%) | ||
| NHL repeat | 616..654 | CDD:271320 | 16/40 (40%) | ||
| NHL repeat | 657..693 | CDD:271320 | 18/35 (51%) | ||
| FXa_inhibition | 763..805 | CDD:464251 | 14/45 (31%) | ||
| YvrE | 854..>992 | CDD:442613 | 55/147 (37%) | ||
| LY | 922..964 | CDD:214531 | 17/48 (35%) | ||
| LY | 973..1007 | CDD:214531 | 15/33 (45%) | ||
| Ldl_recept_a | 1188..1223 | CDD:395011 | 17/36 (47%) | ||
| LDLa | 1227..1259 | CDD:197566 | 19/31 (61%) | ||
| LDLa | 1268..1303 | CDD:238060 | 17/35 (49%) | ||
| LDLa | 1308..1343 | CDD:238060 | 17/36 (47%) | ||
| LDLa | 1356..1387 | CDD:238060 | 16/30 (53%) | ||
| LDLa | 1391..1423 | CDD:197566 | 16/36 (44%) | ||
| LDLa | 1435..1469 | CDD:197566 | 12/40 (30%) | ||
| FXa_inhibition | 1522..1553 | CDD:464251 | 14/30 (47%) | ||
| LY | 1625..1665 | CDD:214531 | 20/39 (51%) | ||
| LY | 1667..1711 | CDD:214531 | 17/44 (39%) | ||
| Ldl_recept_b | 1690..1729 | CDD:459654 | 18/41 (44%) | ||
| LY | 1712..1754 | CDD:214531 | 15/43 (35%) | ||
| LY | 1986..2037 | CDD:214531 | 10/50 (20%) | ||
| FXa_inhibition | 2151..>2179 | CDD:464251 | 13/27 (48%) | ||
| LY | 2259..2305 | CDD:214531 | 18/45 (40%) | ||
| Ldl_recept_b | 2326..2366 | CDD:459654 | 15/39 (38%) | ||
| LY | 2352..2392 | CDD:214531 | 14/40 (35%) | ||
| NHL | 2579..>2711 | CDD:302697 | 46/139 (33%) | ||
| NHL repeat | 2593..2622 | CDD:271320 | 8/28 (29%) | ||
| NHL repeat | 2634..2678 | CDD:271320 | 15/43 (35%) | ||
| LY | 2671..2713 | CDD:214531 | 18/41 (44%) | ||
| LDLa | 2867..2901 | CDD:238060 | 14/33 (42%) | ||
| LDLa | 2906..2941 | CDD:238060 | 16/34 (47%) | ||
| LDLa | 2950..2983 | CDD:238060 | 18/43 (42%) | ||
| LDLa | 3034..3066 | CDD:197566 | 13/31 (42%) | ||
| LDLa | 3080..3115 | CDD:197566 | 14/34 (41%) | ||
| LDLa | 3128..3159 | CDD:238060 | 15/30 (50%) | ||
| LDLa | 3170..3204 | CDD:238060 | 17/38 (45%) | ||
| LDLa | 3210..3242 | CDD:197566 | 13/32 (41%) | ||
| FXa_inhibition | 3259..3287 | CDD:464251 | 10/27 (37%) | ||
| FXa_inhibition | 3293..3329 | CDD:464251 | 15/35 (43%) | ||
| LY | 3362..3394 | CDD:214531 | 16/32 (50%) | ||
| LY | 3406..3448 | CDD:214531 | 15/41 (37%) | ||
| Ldl_recept_b | 3468..3511 | CDD:459654 | 19/42 (45%) | ||
| LY | 3498..3536 | CDD:214531 | 21/37 (57%) | ||
| LY | 3536..3578 | CDD:214531 | 24/41 (59%) | ||
| FXa_inhibition | 3607..3659 | CDD:464251 | 21/51 (41%) | ||
| LDLa | 3663..3696 | CDD:238060 | 18/32 (56%) | ||
| LDLa | 3705..3739 | CDD:238060 | 19/33 (58%) | ||
| LDLa | 3743..3775 | CDD:197566 | 14/31 (45%) | ||
| LDLa | 3784..3817 | CDD:197566 | 18/33 (55%) | ||
| LDLa | 3827..3861 | CDD:197566 | 15/33 (45%) | ||
| LDLa | 3871..3901 | CDD:197566 | 16/29 (55%) | ||
| LDLa | 3913..3947 | CDD:238060 | 21/33 (64%) | ||
| LDLa | 3952..3986 | CDD:238060 | 19/33 (58%) | ||
| LDLa | 3996..4027 | CDD:197566 | 19/30 (63%) | ||
| LDLa | 4043..4071 | CDD:238060 | 16/28 (57%) | ||
| LDLa | 4086..4117 | CDD:238060 | 13/30 (43%) | ||
| EGF_CA | 4163..4194 | CDD:214542 | 14/30 (47%) | ||
| NHL | 4276..>4426 | CDD:302697 | 56/154 (36%) | ||
| NHL repeat | 4291..4336 | CDD:271320 | 14/44 (32%) | ||
| Ldl_recept_b | 4350..4391 | CDD:459654 | 19/40 (48%) | ||
| LY | 4374..4417 | CDD:214531 | 16/42 (38%) | ||
| NHL repeat | 4376..4422 | CDD:271320 | 17/45 (38%) | ||
| Blue background indicates that the domain is not in the aligned region. | |||||